GENETIC SIGNATURES ORD
Genetic Signatures Reports Regional Success of EasyScreen Gastrointestinal Parasite Detection Kit
Genetic Signatures (ASX: GSS) has reported a strong start to the new financial year with the commercial success of its EasyScreen gastrointestinal parasite detection testing kit across all operating regions, and a 20% increase in sales for the quarter to $5.4 million. Revenue contributions came from new business with existing customers in Australia, which experienced […]
ASX biotech stocks benefiting from the COVID-19 story
Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is […]
Genetic Signatures applies to market coronavirus test kit throughout UK and EU
Molecular diagnostics company Genetic Signatures (ASX: GSS) has submitted a European CE in vitro diagnostics registration application for its new 3base EasyScreen coronavirus detection kit. The kit complements the company’s existing EasyScreen respiratory pathogen detection kit which identifies 14 common respiratory pathogens including influenza A and B, rhinovirus and M. pneumoniae and allows a large […]
Genetic Signatures receives green light to market pathogen detection kit in Europe
Molecular diagnostics company Genetic Signatures (ASX: GSS) has received CE-IVD registration, paving the way for the sale of its “EasyScreen” Respiratory Pathogen Detection Kit in Europe. The detection kit can identify 14 common respiratory pathogens, including Influenza A & B, Rhinovirus and M. pneumoniae. The kit allows for rapid detection of pathogens in up to […]
